GSK CEO on US Expansion, M&A, Drug Pipeline, Trump

Published on 14/01/2025 at 01:17 - Modified on 14/01/2025 at 01:33

MT Newswires

+1.35%

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F. Kennedy Jr., President-elect Donald Trump's choice to lead the Department of Health and Human Services. She speaks from the JPMorgan Healthcare Conference.

Bloomberg videos, provided by MT Newswires

Latest news about GSK plc

Britain's life sciences plan gets mixed reception from pharma industry	16/07	RE
FDA staff raises efficacy concerns for Otsuka's PTSD combination treatment	16/07	RE
FTSE 100 retreats from record high as tariff worries resurface	15/07	RE
European Equities Close Lower in Tuesday Trading; EU Targets Industrial Goods in Tariff Row	15/07	MT
GSK : Receives a Sell rating from JP Morgan	15/07	ZD
FDA staff flags eye safety risks for GSK's blood cancer drug	15/07	RE
GSK Shares Rise Ahead of FDA Decision on Blood Cancer Drug	15/07	MT
FDA staff raises eye damage concerns for GSK's blood cancer drug	15/07	RE
GSK : Deutsche Bank reiterates its Neutral rating	15/07	ZD
European Equities Close Mixed in Monday Trading; EU Signals Readiness to Retaliate Against US Tariffs	15/07	MT
GSK-backed ViiV Healthcare Adds Injectable Cabotegravir to HIV Medicines Patent Pool License Deal	15/07	MT
GSK Viiv Extends Cabotegravir Licensing Deal to Include HIV Treatment	14/07	MT
GSK seeks FDA nod for expanded use of RSV vaccine in adults	14/07	RE
Global markets live: Tesla, Gilead, Kenvue, Amazon, Bayer…	14/07
ViiV expands licence to allow generic HIV treatment production for low-income countries	14/07	RE
GSK Seeks FDA Approval to Expand RSV Vaccine Use to At-Risk Adults Aged 18-49	14/07	MT
GSK: seeks FDA approval to expand Arexvy indication	14/07
GSK seeks FDA green light for expanded use of RSV vaccine Arexvy	14/07	AN
DCC sells unit; South32 warns of Mozal impairment	14/07	AN
US FDA Accepts GSK's Application to Expand Indication for RSV Vaccine	14/07	MT
GSK submits Arexvy for adults 18-49 air to FDA	14/07	RE
GSK seeks FDA nod for expanded use of RSV vaccine in adults	14/07	RE
Sector Update: Health Care Stocks Slide Friday Afternoon	11/07	MT
FTSE 100 eases from record levels amid soft GDP	11/07	AN
European Equities Traded in the US as American Depositary Receipts Drop Sharply in Friday Trading	11/07	MT